The DOI matches its Crossref record; 135 of the 137 references it cites were found in a registry or an index.
Adaptive immunity: an emerging player in the progression of NAFLD
Open accessAbstract
In the past decade, nonalcoholic fatty liver disease (NAFLD) has become a leading cause of chronic liver disease and cirrhosis, as well as an important risk factor for hepatocellular carcinoma (HCC). NAFLD encompasses a spectrum of liver lesions, including simple steatosis, steatohepatitis and fibrosis. Although steatosis is often harmless, the lobular inflammation that characterizes nonalcoholic steatohepatitis (NASH) is considered a driving force in the progression of NAFLD. The current view is that innate immune mechanisms represent a key element in supporting hepatic inflammation in NASH. However, increasing evidence points to the role of adaptive immunity as an additional factor promoting liver inflammation. This Review discusses data regarding the role of B cells and T cells in sustaining the progression of NASH to fibrosis and HCC, along with the findings that antigens originating from oxidative stress act as a trigger for immune responses. We also highlight the mechanisms affecting liver immune tolerance in the setting of steatohepatitis that favour lymphocyte activation. Finally, we analyse emerging evidence concerning the possible application of immune modulating treatments in NASH therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In MASLD, this finely tuned immunological equilibrium is perturbed, resulting in chronic low-grade inflammation and inappropriate activation of both innate and adaptive immune responses (Shrestha et al. 2025; Sutti and Albano 2020).”
From The double-edged sword of regulatory T cells in MASLD: from inflammation control to fibrosis promotion (2026) · cites this paper as Sutti and Albano 2020
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Tregs consistently exhibit an increased susceptibility to apoptosis in MASH (Sutti and Albano 2020).”
From The double-edged sword of regulatory T cells in MASLD: from inflammation control to fibrosis promotion (2026) · cites this paper as Sutti and Albano 2020
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“growing evidence has highlighted the critical contribution of immune dysregulation to its pathogenesis.”
From The double-edged sword of regulatory T cells in MASLD: from inflammation control to fibrosis promotion (2026) · cites this paper as Sutti and Albano 2020
In the citing paper
“However, recent evidence indicates that adaptive immunity plays an essential role in the progression of NASH, fibrosis, and HCC.( 6 )”
From The Emerging Role of B Cells in the Pathogenesis of NAFLD (2021) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435
Nonalcoholic Fatty Liver Disease
Rinella, M. E. (2015) · JAMA · doi:10.1001/jama.2015.5370 · Cited by 2,320
Estes, C., Anstee, Q. M., Arias, M., Bantel, H., Bellentani, S., Caballería, J., Colombo, M., Craxì, A., Crespo, J., Day, C. P., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.05.036 · Cited by 2,046
Park, E. J., Lee, J. H., Yu, G.-Y., He, G., Ali, S. R., Holzer, R. G., Österreicher, C. H., Takahashi, H., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2009.12.052 · Cited by 1,764
Immunology in the liver — from homeostasis to disease
Heymann, F., & Tacke, F. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.200 · Cited by 1,180
Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077
The immunology of hepatocellular carcinoma
Ringelhan, M., Pfister, D., O’Connor, T., Pikarsky, E., & Heikenwalder, M. (2018) · Nature Immunology · doi:10.1038/s41590-018-0044-z · Cited by 1,076
Cited by
Sorted by citations
Items 201–300 of 386
Jin, J., Cheng, K., Chen, M., Liang, H., & Zhang, W. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.117394 · Cited by 13
Provera, A., Ramavath, N. N., Gadipudi, L. L., Gigliotti, C. L., Boggio, E. M., Vecchio, C., Stoppa, I., Rolla, R., Boldorini, R. L., Pirisi, M., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1290391 · Cited by 12
Self-citationKhan, I., Kamal, A., & Akhtar, S. (2024) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-024-01387-6 · Cited by 12
Ni, Y., Huang, M., Chen, S., Wang, S., & Chen, J. (2024) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2024149 · Cited by 11
Inflammation and Immunity in Liver Neoplasms: Implications for Future Therapeutic Strategies
Kim, J., & Seki, E. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0726 · Cited by 11
Zhao, C., Lou, F., Li, X., Ma, J., Zhu, Z., Li, H., Zhai, Y., Chen, H., Zhang, Q., Liu, Z., et al. (2021) · PubMed Central · Cited by 11
Gallego‐Durán, R., Montero‐Vallejo, R., Maya‐Miles, D., Lucena, A., Martı́n, F., Ampuero, J., & Romero‐Gómez, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.667354 · Cited by 12
Signaling Pathways Tuning Innate Lymphoid Cell Response to Hepatocellular Carcinoma
Bourayou, E., & Golub, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.846923 · Cited by 11
Immune-related pathogenesis and therapeutic strategies of nonalcoholic steatohepatitis
Chung, K. W., Cho, Y. E., Kim, S.-J., & Hwang, S. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01379-1 · Cited by 11
Alteration in immune function in patients with fatty liver disease
Gregory, S. N., Perati, S. R., & Brown, Z. J. (2022) · Hepatoma Research · doi:10.20517/2394-5079.2022.34 · Cited by 11
Jiang, Y.-C., Wang, Y., Chen, S., Liu, Z., Yang, H.-J., Jiao, Y., & Tang, L.-M. (2023) · Disease Markers · doi:10.1155/2023/2970429 · Cited by 9
Expression of Notch family is altered in non‑alcoholic fatty liver disease
Ding, W., Wu, W., Chen, Y., Chen, H., Fan, J., & Qiao, L. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11249 · Cited by 11
Leng, Y.-R., Zhang, Y.-Q., Cheng, Y., Ye, S.-T., Zheng, Y., He, M.-M., Wu, E.-Y., Kong, L.-Y., & Zhang, H. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107567 · Cited by 12
Type I IFN receptor blockade alleviates liver fibrosis through macrophage-derived STAT3 signaling
Park, S.-J., Garcia Diaz, J., Comlekoglu, T., & Hahn, Y. S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1528382 · Cited by 10
Incretins and MASLD: at the Crossroads of Endocrine and Hepatic Disorders
Farrugia, M. A., Pini, E., Tran, A., Chevalier, N., Anty, R., & Gual, P. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00646-8 · Cited by 11
Yang, R., Yang, H., Jiang, D., Xu, L., Feng, L., & Xing, Y. (2022) · PeerJ · doi:10.7717/peerj.14171 · Cited by 10
Immunotherapy for advanced or recurrent hepatocellular carcinoma
Luo, Y.-Z., & Zhu, H. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i3.405 · Cited by 11
Insights into the role of vitamin D in targeting the culprits of non-alcoholic fatty liver disease
Abdelrahman, B. A., El-Khatib, A. S., & Attia, Y. M. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122124 · Cited by 10
Brugger, M., Laschinger, M., Lampl, S., Schneider, A., Manske, K., Esfandyari, D., Hüser, N., Hartmann, D., Steiger, K., Engelhardt, S. H., et al. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100465 · Cited by 14
Namdar, A. B., Ahadi, M., Hoseini, S. M., Vosooghinia, H., Rajablou, H., Farsi, S., Zangouei, A., & Rahimi, H. R. (2023) · PubMed Central · doi:10.22038/ajp.2023.21919 · Cited by 10
Sutti, S., & Albano, E. (2022) · Redox Experimental Medicine · doi:10.1530/rem-22-0002 · Cited by 11
Self-citationLiu, Y. (2025) · Liver Cancer · doi:10.1159/000550163 · Cited by 12
Steatosis, Steatohepatitis and Cancer Immunotherapy: An Intricate Story
Cataldi, M., Manco, F., & Tarantino, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312947 · Cited by 9
Wang, C., Yan, J., Zhang, S., Xie, Y., Nie, Y., Chen, Z., & Xu, S. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.771219 · Cited by 10
Liu, Z., Li, Y., & Caihong, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.857892 · Cited by 9
Kytikovа, O. Y., Novgorodtseva, T. P., Denisenko, Y., & Kovalevskiy, D. A. (2020) · Russian Journal of Gastroenterology Hepatology Coloproctology · doi:10.22416/1382-4376-2020-30-2-15-25 · Cited by 9
Ma, C., Wang, C., Zhang, Y., Zhou, H., & Li, Y. (2021) · Current Molecular Pharmacology · doi:10.2174/1874467215666211217120448 · Cited by 8
Kim, H. J., Park, S. J., Park, H. K., Byun, D. W., Suh, K., & Yoo, M. H. (2022) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15865 · Cited by 9
Mining Gut Microbiota From Bariatric Surgery for MAFLD
Wu, W., Chen, Y., Lee, P., Yang, P., Chang, C., Liu, K., Hsu, C., Huang, C., Chuang, H.-L., Sheen, L., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.612946 · Cited by 9
Tang, C., Peng, D., Zong, K., Wu, Z., Gong, M., Li, H., Huang, Z., & Li, S. (2024) · BMC Gastroenterology · doi:10.1186/s12876-024-03565-5 · Cited by 8
Wang, S., Xu, Z., Wang, Z., Yi, X., & Wu, J. (2025) · BMC Genomics · doi:10.1186/s12864-025-11377-4 · Cited by 8
A nem alkoholos zsírmájbetegség és a 2-es típusú cukorbetegség.
Pár, A., Wittmann, I., & Pár, G. (2022) · Orvosi Hetilap · doi:10.1556/650.2022.32479 · Cited by 8
Zhong, B., Xie, Z., Zhang, J., Xie, X., Xie, Y.-K., Xie, B., Wang, J., & Liu, C.-B. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1360974 · Cited by 9
Papadopoulos, G., Giannousi, E., Avdi, A. P., Velliou, R.-I., Nikolakopoulou, P., & Chatzigeorgiou, A. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1343806 · Cited by 8
Sung, P. S. (2020) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2020.050 · Cited by 8
The Roles of T Cells in the Development of Metabolic Dysfunction‐Associated Steatohepatitis
Ge, Z., Wu, Q., Lv, C., & He, Q. (2025) · Immunology · doi:10.1111/imm.13943 · Cited by 7
Programmed cell death 1 genetic variant and liver damage in nonalcoholic fatty liver disease
Pipitone, R. M., Malvestiti, F., Pennisi, G., Jamialahmadi, O., Dongiovanni, P., Bertolazzi, G., Pihlajamäki, J., Yki‐Järvinen, H., Gentilucci, U. V., Tavaglione, F., et al. (2023) · Liver International · doi:10.1111/liv.15586 · Cited by 7
Kado, A., Tsutsumi, T., Yotsuyanagi, H., Ikeuchi, K., Okushin, K., Moriya, K., Koike, K., & Fujishiro, M. (2023) · Journal of Gastroenterology · doi:10.1007/s00535-023-02038-y · Cited by 7
Jackson, K. G., Zhao, D., Su, L., Lipp, M. K., Toler, C., Idowu, M. O., Yan, Q., Wang, X., Gurley, E. C., Wu, N., et al. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000570 · Cited by 8
Targeting Histone Deacetylase 11 with a Highly Selective Inhibitor for the Treatment of MASLD
Zhang, F., Yue, K., Sun, S., Lu, S., Jia, G., Zha, Y., Zhang, S., Chou, C. J., Liao, C., Li, X., et al. (2025) · Advanced Science · doi:10.1002/advs.202412903 · Cited by 8
Lee, S. Y., Lee, S.-B., Kwon, G.-H., Song, S. H., Park, J. H., Kim, M. J., Eom, J. A., Lee, K. J., Yoon, S. J., Park, H., et al. (2025) · The Journal of Microbiology · doi:10.71150/jm.2411002 · Cited by 7
Molecular mechanisms of liver carcinogenesis related to metabolic syndrome
Campani, C., & Nault, J. (2022) · Hepatoma Research · doi:10.20517/2394-5079.2021.126 · Cited by 4
Lv, Y., Lin, Z., Chen, J., Jiang, K., Wang, A., Wang, B., Wu, Y., Xu, Z., Wang, J., & Yao, W. (2023) · Food and Chemical Toxicology · doi:10.1016/j.fct.2023.113860 · Cited by 7
The paradox role of cytotoxic T-lymphocytes in NAFLD-associated hepatocellular carcinoma.
Albano, E., & Sutti, S. (2021) · Hepatobiliary surgery and nutrition · doi:10.21037/hbsn-21-243 · Cited by 6
Self-citationThe Role of CD4+T Cells in Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma
Miao, Y., Li, Z., Feng, J., Lei, X., Shan, J., Qian, C., & Li, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25136895 · Cited by 8
Yang, M. J., Liu, S., Sui, Y., & Zhang, C. (2024) · Immunometabolism · doi:10.1097/in9.0000000000000047 · Cited by 6
Gao, L., Fang, H., Zhao, Z., Luo, W., Gong, J., & Gong, J. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1486700 · Cited by 6
Hupa‐Breier, K. L., Schenk, H. J., Campos-Murguía, A., Wellhöner, F., Heidrich, B., Dywicki, J., Hartleben, B., Böker, C., Mall, J. W., Terkamp, C., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102104 · Cited by 6
Fatty liver progression and carcinogenesis: Beware of pathogenic T cells
Hirsova, P., & Gores, G. J. (2021) · Med · doi:10.1016/j.medj.2021.04.020 · Cited by 6
Mechanisms of Inflammasome Activation and Involvement in Liver Disease
Baral, A. (2024) · Journal of Molecular Pathology · doi:10.3390/jmp5020011 · Cited by 6
Luo, Z., Huang, C., Chen, J., Chen, Y., Yang, H., Wu, Q., Lu, F., & Zhang, T. E. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1323859 · Cited by 6
Redox Control of the Immune Response in the Hepatic Progenitor Cell Niche
Bellanti, F., Pannone, G., Tartaglia, N., & Serviddio, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00295 · Cited by 6
Role of CD4+ T-cells in the pathology of non-alcoholic fatty liver disease and related diseases
Seike, T., Mizukoshi, E., & Kaneko, S. (2021) · Hepatoma Research · doi:10.20517/2394-5079.2021.46 · Cited by 6
Lee, H. A. (2024) · Ewha Medical Journal · doi:10.12771/emj.2024.e65 · Cited by 5
Nanotherapy targeting liver sinusoidal endothelial cells in liver fibrosis
Zhang, L., Ru, J.-W., Liang, S.-Q., Zhang, M.-M., Zhang, C.-Y., Liu, J.-Q., Wang, Y., Zhou, T., Cheng, X. W., Xing, L., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114864 · Cited by 7
Prevalence of Steatotic Liver Disease Among US Adults with Rheumatoid Arthritis
Vassilopoulos, A., Kalligeros, M., Vassilopoulos, S., Shehadeh, F., Benitez, G., Kaczynski, M., Lazaridou, I., Promrat, K., Wands, J. R., & Mylonakis, E. E. (2024) · Digestive Diseases and Sciences · doi:10.1007/s10620-023-08225-4 · Cited by 5
Fang, Z., Liu, C.-X., Cheng, Y., Ji, Y., & Liu, C. (2025) · Life Science · doi:10.1016/j.lfs.2025.123377 · Cited by 5
Koelsch, N. J., Mirshahi, F., Aqbi, H. F., Seneshaw, M., Idowu, M. O., Olex, A. L., Sanyal, A. J., & Manjili, M. H. (2025) · Liver International · doi:10.1111/liv.70110 · Cited by 7
Lee, J., Hoon, J., Cho, H. S., Yang, K., Yang, H., Nam, H., Byun, M. Y., Cho, S. K., Park, J., Ko, H. W., et al. (2025) · Journal of Gastroenterology · doi:10.1007/s00535-025-02285-1 · Cited by 6
Brea, R., Valdecantos, M. P., Rada, P., Alén, R., García‐Monzón, C., Boscá, L., Fuertes‐Agudo, M., Casado, M., Martín‐Sanz, P., & Valverde, Á. M. (2021) · Aging · doi:10.18632/aging.202884 · Cited by 5
Identification of Key Biomarkers and Immune Infiltration in Liver Tissue after Bariatric Surgery
Zhang, X., Li, J., Liu, T., Zhao, M., Liang, B., Chen, H., & Zhang, Z. (2022) · Disease Markers · doi:10.1155/2022/4369329 · Cited by 5
RetractedWu, K., Zhu, J., Ma, Y., Zhou, Y., Lin, Q., Tu, T., & Liu, Q. (2023) · Scientific Reports · doi:10.1038/s41598-023-44884-z · Cited by 5
From complement to complosome in non‐alcoholic fatty liver disease: When location matters
Nguyen, V., Hughes, T. R., & Zhou, Y. (2023) · Liver International · doi:10.1111/liv.15796 · Cited by 6
Arnold, J., Idalsoaga, F. J., Díaz, L. A., Cabrera, D., Francisco Barrera, M., Arab, J. P., & Arrese, M. A. (2024) · Current Hepatology Reports · doi:10.1007/s11901-023-00629-0 · Cited by 5
SERPINB3 in fibrogenic chronic liver diseases and primary liver cancers
Pontisso, P., & Parola, M. (2024) · Exploration of Digestive Diseases · doi:10.37349/edd.2024.00038 · Cited by 5
Liu, A., Xiaoling, D., Hou, S., Xi, Y., & Xu, K. (2025) · Cells · doi:10.3390/cells14100740 · Cited by 5
Pathogenesis of NAFLD-Related Hepatocellular Carcinoma: An Up-to-Date Review
Gao, Y., Zhu, R., Dong, J., & Li, Z. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s400231 · Cited by 7
Adisa, R. A., & Sulaimon, L. A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.105473 · Cited by 6
Xin, Q., Tian, F., Qiao, H.-H., Li, G., Wang, Y., Li, L.-X., Zhang, L., Song, N., Chen, K., Yan, Y.-X., et al. (2026) · Materials Today · doi:10.1016/j.mattod.2026.103294 · Cited by 3
Hu, Q. N., Luo, Y., He, H., Chen, H., & Liao, D. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e35453 · Cited by 5
Chen, Y., Jia, B., Tong, X., Yin, S., Ni, W., Zhao, Q., Shi, J., & Li, J. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000864 · Cited by 5
Metabolic dysfunction-associated steatotic liver disease: pathogenesis and novel treatment options
Ren, R., Liang, X., & Wei, X. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00486-5 · Cited by 5
He, J., Xiao, C., Li, C., Yang, F., & Du, C. (2023) · Liver Research · doi:10.1016/j.livres.2023.06.001 · Cited by 4
Zhang, H., He, Y., Zhao, Y., Axinbai, M., Hu, Y., Liu, S., Kong, J., Sun, J., & Zhang, L. (2024) · Hereditas · doi:10.1186/s41065-024-00309-z · Cited by 4
Encouraging specific biomarkers-based therapeutic strategies for hepatocellular carcinoma
Yao, M., Yang, J., Wang, D., Wang, L., Chen, Y., & Yao, D. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i11.3321 · Cited by 4
Eisenstein, E. L., Peterson, E. D., Jollis, J. G., Tardiff, B. E., Califf, R. M., Knight, J. D., & Mark, D. B. (1997) · Europe PMC (PubMed Central) · Cited by 4
Mechanisms of innate immune cells in Metabolic dysfunction-associated steatotic liver disease
Yao, Y., Wu, Q., Fan, B., Peng, X., Sheng, M., & Wang, F. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1599748 · Cited by 4
Rodriguez-Aguillon, K. O., González-González, M. L., Calvillo‐Rodríguez, K. M., Rodrı́guez-Padilla, C., & Martínez‐Torres, A. C. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1773872 · Cited by 3
Li, X., Jin, K., Fang, J., Ma, X., He, J., Lu, A., Jia, Z., & Shi, A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1835197 · Cited by 4
Key genes involved in nonalcoholic steatohepatitis improvement after bariatric surgery
Chen, X., Deng, S., Sun, Y., Bai, Y., Wang, Y., & Yang, Y. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1338889 · Cited by 4
Different aspects of immunological profile in patients with Non-Alcoholic Fatty liver disease.
Osman, H. A., Tag-Adeen, M., Abdelaal, U., Elgezawy, E., Nasif, K. A., & Nafady, A. (2024) · Acta gastro-enterologica Belgica · doi:10.51821/87.2.12205 · Cited by 3
Hepatocellular Carcinoma: Aetiology and Mechanisms of Development. A Literature Review
Меньшиков, К. В., Султанбаев, А. В., Мусин, Ш. И., Rakhmatullina, I. R., Menshikovа, I. A., Abdeev, R. R., Султанбаева, Н. И., Popova, E. V., & Serebrennikov, G. A. (2022) · Creative Surgery and Oncology · doi:10.24060/2076-3093-2022-12-2-139-150 · Cited by 4
Niedecker, R. W., Delaney, J. A., Doyle, M. F., Sparks, A. D., Sitlani, C. M., Bůžková, P., Zeb, I., Tracy, R. P., Psaty, B. M., Budoff, M. J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1243526 · Cited by 3
Liguori, A., D’Ambrosio, F., Napodano, C., Gentili, V., Giustiniani, M. C., Pompili, M., Grieco, A., Rapaccini, G., Urbani, A., Gasbarrini, A., et al. (2024) · Liver International · doi:10.1111/liv.16036 · Cited by 3
Xiang, W., Cheng, S., Peng, Y., Jin, Q., & Yang, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-76560-1 · Cited by 3
Wang, L., Lu, Y.-M., Wang, Y., Wang, Y., Fang, R.-F., Sai, W., Yao, D., & Yao, M. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i47.5055 · Cited by 3
Can Walnut Serve as a Magic Bullet for the Management of Non-Alcoholic Fatty Liver Disease?
Kim, M.-Y., & Choi, S. (2020) · Applied Sciences · doi:10.3390/app11010218 · Cited by 3
Gjurašin, B., Butić, I., Vince, A., & Papić, N. (2021) · Infektološki glasnik · doi:10.37797/ig.40.4.2 · Cited by 3
The Impact of IFNλ4 on the Adaptive Immune Response to SARS-CoV-2 Infection
Møhlenberg, M., Monrad, I., Vibholm, L. K., Nielsen, S. S. F., Frattari, G. S., Schleimann, M. H., Olesen, R., Kjølby, M., Gunst, J. D., Søgaard, O. S., et al. (2021) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2021.0106 · Cited by 3
Kozaczek, M., Kong, B. C., Bottje, W. G., & Hakkak, R. (2021) · Journal of Medicinal Food · doi:10.1089/jmf.2021.0088 · Cited by 3
Jia, J., Yuan, G., Wang, Z., Xia, Y., Pan, Y., Zhang, L. R., Tang, F., Yu, X., Yang, Z., Wang, D., et al. (2022) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530323666221208105720 · Cited by 4
Li, J., Bai, X., Ni, W., Yin, S., Shi, J., Yang, Y., & Li, J. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115553 · Cited by 4
Shao, Y.-J., Zhang, Y.-S., Yin, L., Yin, J.-H., & Lin, Y.-F. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1737437 · Cited by 2
CHARACTERISTICS OF THE IMMUNE STATUS IN PATIENTS WITH DECOMPENSATION OF LIVER CIRRHOSIS
Ivanova, A. L., Карзакова, Л. М., Odintsova, A. V., Игоревич, К. С., Bagildinskaya, M. V., & Vladimirovna, Z. N. (2023) · Acta medica Eurasica · doi:10.47026/2413-4864-2023-1-53-62 · Cited by 2
Molecular profiling in the management of hepatocellular carcinoma
Soliman, N., Saharia, A., Abdelrahim, M., & Connor, A. A. (2023) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000001124 · Cited by 2
Burmeister, Y., Weyer, K., Dörre, A., & Seilheimer, B. (2023) · Biomedicines · doi:10.3390/biomedicines11123216 · Cited by 2
Shi, P., Chen, X., Cao, J., Feng, Z., & Xue, B. (2024) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/0113862073344422240906051007 · Cited by 2
Yang, X., Zhuo, S., Zhuang, H., & Fang, T. (2024) · Journal of Health Population and Nutrition · doi:10.1186/s41043-024-00670-9 · Cited by 2
Matboli, M., Saad, M., Ahmed, M. F., Hasanin, A. H., Ellithy, G., Abdel-Wahab, M. A.-K., Eltantawy, E. H. B., Hamam, G. G., Hamoud, A., ElShafei, M. M., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118086 · Cited by 2
Pagano, S., Somm, E., Jornayvaz, F. R., & Vuilleumier, N. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70092 · Cited by 2
Metadata
- Authors
- Sutti, S., & Albano, E.
- Affiliations
- Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT)
- Corresponding author
- Albano, Emanuele
- Venue
- Nature Reviews Gastroenterology & Hepatology
- Published
- 2019-10-11
- Volume
- 17
- Issue
- 2
- Pages
- 81-92
- ISSN
- 1759-5045 (ISSN-L)
- 1759-5053
- PMC
- PMC7222953
- OpenAlex
- W2979371456
- Cited by
- 374
- References
- 137
- Citations by year
- 2026: 35 · 2025: 42 · 2024: 67 · 2023: 70 · 2022: 75 · 2021: 55 · 2020: 27 · 2019: 1
- FWCI
- 5.94
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Nature Reviews Gastroenterology & Hepatology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Fondazione Cariplo (2011-0470)
- Ministero dell’Istruzione, dell’Università e della Ricerca (FAR 2015)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, adaptive immunity, B cells, T cells, liver inflammation, liver fibrosis, hepatocellular carcinoma, immune tolerance, immunomodulatory therapy, disease progression
- MeSH terms
- B-Lymphocytes, Carcinoma, Hepatocellular, Humans, Immune Tolerance, Immunity, Innate, Liver Cirrhosis, Liver Neoplasms, T-Lymphocytes, Oxidative Stress, Disease Progression, Natural Killer T-Cells, Adaptive Immunity, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
